tocilizumab in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results TOCOVID, 0 0.99 [0.02; 50.02]
0.99 [0.02 ; 50.02 ] TOCOVID, 0 1 0% 270 NA not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
TOCOVID, 0 0.99 [0.02; 50.02]
1.46 [0.42 ; 5.04 ] BACC Bay Tocilizumab Trial, 2020, TOCOVID, 0 2 0% 512 low not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
1.11 [0.59 ; 2.09 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
1.06 [0.80 ; 1.41 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
NCT04310228-FAVI (Zhao), 2020 (REV) 0.28 [0.01; 7.92]
0.78 [0.37 ; 1.68 ] BACC Bay Tocilizumab Trial, 2020, NCT04310228-FAVI (Zhao), 2020 (REV) 2 0% 254 low not evaluable radiologic improvement (14-day)detailed results NCT04310228-FAVI (Zhao), 2020 (REV) 3.13 [0.61; 15.92]
3.13 [0.61 ; 15.92 ] NCT04310228-FAVI (Zhao), 2020 (REV) 1 0% NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
1.21 [0.58 ; 2.53 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable adverse eventsdetailed results NCT04310228-FAVI (Zhao), 2020 (REV) 1.67 [0.15; 18.88]
1.67 [0.15 ; 18.88 ] NCT04310228-FAVI (Zhao), 2020 (REV) 1 0% 12 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-16 09:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 94
- treatments: 395
- roots T: 290